Eledon Pharmaceuticals Overview
Latest P/E ratio for Eledon Pharmaceuticals: -3.89 — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-3.89
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Eledon Pharmaceuticals (ELDN) currently reports a P/E ratio of -3.89. That is below the Healthcare sector average of 27.42. Use the charts on this page to explore Eledon Pharmaceuticals's P/E ratio history and peer comparisons.
Eledon Pharmaceuticals's P/E ratio of -3.89 is lower than the Healthcare sector average of 27.42. That is roughly 114.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates Eledon Pharmaceuticals's market price to a fundamental measure such as earnings, sales, or book value. At -3.89, ELDN can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of -3.89, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 27.42. From there, open related valuation or income-statement pages for Eledon Pharmaceuticals, and consider following ELDN for alerts when major investors trade the stock.
Eledon Pharmaceuticals is classified in the Healthcare sector. On P/E ratio, it currently shows -3.89 versus a sector average near 27.42. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ELDN with unrelated industries.
